News Cytosorbents Corporation

Equities

CTSO

US23283X2062

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
0.79 ^USD	-0.97%		-17.71%	-28.83%

Mar. 15	Cytosorbents Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 14	Earnings Flash (CTSO) CYTOSORBENTS Reports Q4 Revenue $8.7M, vs. Street Est of $9.8M	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting	Apr. 17	GL
Cytosorbents Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Earnings Flash (CTSO) CYTOSORBENTS Reports Q4 Revenue $8.7M, vs. Street Est of $9.8M	Mar. 14	MT
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results	Mar. 14	GL
Transcript : Cytosorbents Corporation, Q4 2023 Earnings Call, Mar 14, 2024	Mar. 14
CytoSorbents to Report Fiscal 2023 Operating and Financial Results	Mar. 06	GL
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference	Feb. 08	GL
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference	Feb. 08	AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO	Jan. 30	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO	Jan. 22	PR
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients	Jan. 17	GL
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients	Jan. 17	AQ
Cytosorbents Corporation Reports Excellent Outcomes from A Groundbreaking Randomized Controlled Trial Using Cytosorb® Blood Purification During Heart Transplant, Recently Published in the European Society of Cardiology Journal, Esc Heart Failure	Jan. 17	CI
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO	Jan. 14	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO	Jan. 06	PR
North American Morning Briefing : Stock Futures Struggle After Weak China Data	Jan. 02	DJ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO	Dec. 29	PR
HC Wainwright Downgrades Cytosorbents to Neutral From Buy, Cuts Price Target to $1 From $5.50	Dec. 29	MT
S&P 500 ekes out meager gains, flirts with bull market confirmation	Dec. 28	RE
Sector Update: Health Care Stocks Rise in Late Afternoon	Dec. 28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cytosorbents Corporation

Equities

CTSO

US23283X2062

Summary

Filters